NRD
MED icon

Nebula Research & Development’s Medifast MED Stock Holding History

Nebula Research & Development’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,617
Closed -$369K – 948
2024
Q1 		$369K Buy
+9,617
New +$466K 0.08% 461
2023
Q3 		– Sell
-2,626
Closed -$242K – 588
2023
Q2 		$242K Buy
+2,626
New +$234K 0.18% 239

Other funds holding MED

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Nebula Research & Development's MED Position: Q2 2024 in Review

Nebula Research & Development sold out of Medifast (MED) in Q2 2024, closing a stake of 9,617 shares — an estimated $369K sold.

Nebula Research & Development first reported a position in MED in Q2 2023 and held it in 2 quarters. The position peaked at $369K in Q1 2024. 158 funds tracked by Wall St. Rank hold MED as of Q2 2024.

  • Nebula Research & Development reported no remaining Medifast position as of Q2 2024 after selling out during the quarter.
  • Nebula Research & Development sold 9,617 Medifast shares in Q2 2024, an estimated $369K.
  • Nebula Research & Development first reported a position in Medifast in Q2 2023 and held it in 2 quarters.
  • Nebula Research & Development's Medifast position peaked at $369K in Q1 2024.
  • 158 funds tracked by Wall St. Rank held Medifast as of Q2 2024.

Based on Nebula Research & Development's 13F filing for Q2 2024, filed 14 Aug 2024.